TPSD1

Across TCGA pan-cancer cohorts, TPSD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TPSD1 data layer compared with 19 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TPSD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TPSD1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where TPSD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.823	0.320	<.001	54	view →
CCRCC	OS	Tertile	All	0.905	1.000	.021	18	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	14	view →
HNSC	DFS	Tertile	III,IV	0.711	0.914	.007	4	view →
PDAC	OS	Tertile	All	0.390	0.622	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TPSD1–LUAD (DFS)

Open the LUAD breakdown →